Clinical Trial Update: Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial assessing safety and pharmacology of SNX-5422 plus Everolimus in neuroendocrine tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• Everolimus (everolimus)
• SNX-5422

Snippet

Sponsor: Esanex Inc. | Conditions: Cancer | Phase 1 | Status: COMPLETED